Key highlights from AACR poster:
- XMT-1592 is a clinical-stage NaPi2b-targeted site-specific ADC, DAR6, that combines the novel Dolasynthen and the Synaffix GlycoConnect™ platforms
- XMT-1592 induced sustained tumor regressions in an ovarian tumor xenograft and a lung adenocarcinoma patient-derived PDX
- XMT-1592 (with GlycoConnect™) outperformed a stochastically conjugated ADC with the same antibody, payload, with similar DAR, exhibiting improved anti-tumor activity, pharmacokinetics, and clinical pathology
